About UsResearch & DevelopmentBusinessInvestor RelationsIndustry Info

Businesses
 
The Contract Research & Manufacturing Services

We have completely integrated R&D, technology and engineering capabilities that enables us to be cost effective partners on a sustainable basis. We have built strong alliances and continuing relationships with top global generic companies. We offer our customers, services related to research & development and formulation development, intermediates, advance intermediates and fine chemicals. The Contract Manufacturing Division is being set up to address the challenges & opportunities created due to increasing R&D costs, low R&D productivity, impending patent expirations and at the same time, pressure to reduce healthcare costs. This in turn has propelled global pharma majors to cut costs and improve overall profitability. This is expected to translate into a strong outsourcing potential for low cost manufacturing destinations like India and China.

The Division would be exploring Joint Ventures / Strategic Alliances with Manufacturers and IP companies in the Specialty Chemicals sector to partner in areas ranging from custom synthesis to manufacturing.

India offers the following advantages to innovator companies
Strong chemistry skills as demonstrated in the domestic market.
Low labour cost (Labour cost is 1/7th of that in USA).
Lower cost of manufacturing (30-40%) as compared to western countries with same quality.
Integrated business model creating a 'one stop' shop for innovators.
India has 6 times the number of trained chemists as the US, which is available at 1/10th of cost.
With over 75 USFDA approved plants, India has the highest number of FDA approved plants outside the US.
Abundant English speaking skilled manpower.
High quality telecom and IT infrastructure.
Most importantly Indian companies have better regulatory skills like IPR adherence.

Current Status
The Company has alliances with the top 8 MNC generic companies for contract manufacturing of 30 generic products for the European markets.
Licensing agreements in place with numerous companies for development and supply of products for 7-10 years.

Strategy

The company plans to enhance its product portfolio with the addition of 12-13 products p.a.

Offering CRAMS services for existing and emerging markets is envisaged as one of the major driver and revenue earner for the company.

 


 © Copyright 2008 Marksans Pharma.